elhamkhani
/
Test2
/
Login
Register
TriplyDB
Test2
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
GraphQL
BETA
Graphs
1
Q47374718-1DDBE1B0-1746-4DCD-BC1F-B6E848F82A6F
Q47374718-1DDBE1B0-1746-4DCD-BC1F-B6E848F82A6F
BestRank
Statement
http://www.wikidata.org/entity/statement/Q47374718-1DDBE1B0-1746-4DCD-BC1F-B6E848F82A6F
A novel and selective sodium-glucose cotransporter-2 inhibitor, tofogliflozin, improves glycaemic control and lowers body weight in patients with type 2 diabetes mellitus.
P2860
Q47374718-1DDBE1B0-1746-4DCD-BC1F-B6E848F82A6F
BestRank
Statement
http://www.wikidata.org/entity/statement/Q47374718-1DDBE1B0-1746-4DCD-BC1F-B6E848F82A6F
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
4337818934d40659f2c4f22ca8e2f6412a23f3fb
P2860
Safety, tolerability, pharmacokinetics and pharmacodynamics following 4 weeks' treatment with empagliflozin once daily in patients with type 2 diabetes.